Table 3.

Adjusted^a Relative Risks and 95% Confidence Intervals for the Association Between Baseline Status of Menopausal Hormone Therapy Use and Incident Invasive Colon Cancer, by Stage of Disease at Diagnosis,^b Among Perimenopausal and Postmenopausal Participants in the California Teachers Study, 1995–2006

Status of HT Use at Baseline	Localized			Regional			Distant
	No. of Cases	Relative Risk	95% Confidence Interval	No. of Cases	Relative Risk	95% Confidence Interval	No. of Cases	Relative Risk	95% Confidence Interval
Ever HT use, at baseline
Never HT user	44	1.00	Referent	60	1.00	Referent	39	1.00	Referent
Ever HT user, estrogen therapy only	48	0.80	0.53, 1.23	66	0.84	0.59, 1.20	25	0.50	0.30, 0.84
Ever HT user, estrogen + progestin therapy only	14	1.06	0.57, 2.00	9	0.49	0.24, 0.99	9	0.80	0.38, 1.67
Ever HT user, mixed formulations	53	1.17	0.76, 1.78	46	0.65	0.43, 0.98	17	0.42	0.23, 0.76
Former or recent HT use, at baseline
Never HT user	44	1.00	Referent	60	1.00	Referent	39	1.00	Referent
Former HT user	34	0.98	0.61, 1.55	37	0.84	0.55, 1.27	24	0.95	0.57, 1.58
Recent HT user	81	0.96	0.65, 1.40	84	0.68	0.48, 0.96	27	0.33	0.20, 0.56

Abbreviation: HT, hormone therapy.

^aAdjusted for race (as shown), body mass index (continuous measure), and physical activity (low, intermediate, high) and stratified by age at cohort entry (continuous measure in years).

^bParticipants with missing stage (n = 12) are not shown in the table.